Actualités Eyetech Pharmaceuticals (MM) - EYET | Actions NASDAQ

OSI Pharmaceuticals and Eyetech Pharmaceuticals Confirm November 14th Closing

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Eyetech Pharmaceuticals, Inc. (NASDAQ: EYET) today announced that the closing of the OSI acquisition...

Eyetech Provides Update on Status of Pending Acquisition by OSI Pharmaceuticals

Stockholders Overwhelmingly Approve Merger NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET) provided an...

Eyetech Reports Third Quarter 2005 Financial Results

Company achieves operating profitability, excluding certain charges, based on total revenue of $67.4 million and net product revenue of $55.5...

Eyetech Announces Enrollment of the First Patient in a Phase 3 Clinical Trial of Macugen(R) (pegaptanib sodium injection) in Dia

Phase 2 study of Macugen in diabetic macular edema (DME) published in the October issue of Ophthalmology NEW YORK, Oct. 17...

Recent Analyses Suggest That Treatment With Macugen(R) (pegaptanib sodium injection) May Provide Better Results for Patients Wit

Retrospective, subgroup analyses of the VISION study suggest that treatment of early disease with Macugen may further reduce the risk of vision...

Macugen(R) (pegaptanib sodium injection) Receives Positive Opinion for Treatment of Neovascular Age-Related Macular Degeneration

NEW YORK, Sept. 16 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET) announced today that the Committee for Medicinal...

OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement

Acquisition Projected to be Accretive and Generate Combined 2006 Revenues of Over $600 Million MELVILLE, N.Y. and NEW YORK, Aug. 21...

OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement; Acquisition Projected to be Acc

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Eyetech Pharmaceuticals, Inc. (NASDAQ: EYET) today announced that they have entered into a definitive...

Macugen(R) (pegaptanib sodium injection) Named Innovative Pharmaceutical Product Of The Year At The 2005 Pharmaceutical Achievem

Award recognizes Macugen's breakthrough technology as the first anti- angiogenic treatment approved in ophthalmology and the first aptamer therapy...

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eyetech Pharmaceuticals (MM) (EYET)

Outils de qualité professionnelle, pour des investisseurs individuels.

EYET Actualités

OSI Pharmaceuticals and Eyetech Pharmaceuticals Confirm November 14th Closing

Eyetech Provides Update on Status of Pending Acquisition by OSI Pharmaceuticals

Eyetech Reports Third Quarter 2005 Financial Results

Eyetech Announces Enrollment of the First Patient in a Phase 3 Clinical Trial of Macugen(R) (pegaptanib sodium injection) in Dia

Recent Analyses Suggest That Treatment With Macugen(R) (pegaptanib sodium injection) May Provide Better Results for Patients Wit

Macugen(R) (pegaptanib sodium injection) Receives Positive Opinion for Treatment of Neovascular Age-Related Macular Degeneration

OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement

OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement; Acquisition Projected to be Acc

Macugen(R) (pegaptanib sodium injection) Named Innovative Pharmaceutical Product Of The Year At The 2005 Pharmaceutical Achievem

Eyetech Reports Second Quarter 2005 Financial Results

Eyetech and Pfizer Comment on Data Presented at Meeting of Retinal Specialists

Eyetech To Announce Second Quarter 2005 Financial Results On July 27, 2005

Eyetech Raises Full-Year Sales Forecast for Macugen(R) (pegaptanib sodium injection)

Eyetech Vision Day to Preview Future of Macugen Franchise

Eyetech to Host Vision Day on Wednesday, June 22

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eyetech Pharmaceuticals (MM) (EYET) Actualités

Eyetech Pharmaceuticals (MM) (EYET)

Outils de qualité professionnelle, pour des investisseurs individuels.

EYET Actualités

OSI Pharmaceuticals and Eyetech Pharmaceuticals Confirm November 14th Closing

Eyetech Provides Update on Status of Pending Acquisition by OSI Pharmaceuticals

Eyetech Reports Third Quarter 2005 Financial Results

Eyetech Announces Enrollment of the First Patient in a Phase 3 Clinical Trial of Macugen(R) (pegaptanib sodium injection) in Dia

Recent Analyses Suggest That Treatment With Macugen(R) (pegaptanib sodium injection) May Provide Better Results for Patients Wit

Macugen(R) (pegaptanib sodium injection) Receives Positive Opinion for Treatment of Neovascular Age-Related Macular Degeneration

OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement

OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement; Acquisition Projected to be Acc

Macugen(R) (pegaptanib sodium injection) Named Innovative Pharmaceutical Product Of The Year At The 2005 Pharmaceutical Achievem

Eyetech Reports Second Quarter 2005 Financial Results

Eyetech and Pfizer Comment on Data Presented at Meeting of Retinal Specialists

Eyetech To Announce Second Quarter 2005 Financial Results On July 27, 2005

Eyetech Raises Full-Year Sales Forecast for Macugen(R) (pegaptanib sodium injection)

Eyetech Vision Day to Preview Future of Macugen Franchise

Eyetech to Host Vision Day on Wednesday, June 22

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres